Side-by-side comparison of AI visibility scores, market position, and capabilities
Israeli AI drug discovery raised $25M (Bessemer). 40+ programs. CEO co-patented with Jennifer Doudna (Jan 2026).
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.\n\nConverge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.\n\nConverge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery.
FY2025 (ended Mar 31, 2025): JPY 21.6887T (+6.2%) | Operating Profit: JPY 1.2134T (-12.2%) | FY2024: JPY 20.4286T (+20.8%) | Q3 FY2024 (9 months): Op Profit JPY 1.1399T, margin 7.0% | Auto sales down 297k (Asia impact) | FY2026 guidance: Net profit JPY 250B (-70.1%), Revenue JPY 20.3T (-6.4%)
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded into automobiles, power equipment, marine engines, and aerospace, becoming one of the largest and most diversified mobility companies in the world. With over 90 million vehicles sold globally and a reputation built on engineering reliability, fuel efficiency, and innovation, Honda operates manufacturing facilities across more than 30 countries on six continents.\n\nHonda's automotive lineup ranges from mass-market sedans and SUVs — including the best-selling Civic and CR-V — to trucks, minivans, and the premium Acura brand. The company is executing a major pivot to electrification through the Honda 0 Series, a new EV architecture designed from the ground up for battery-electric vehicles launching in 2026. Honda's partnership with General Motors on battery technology, combined with its investment in solid-state battery development, reflects a multi-path electrification strategy designed to hedge technology risk while building scale.\n\nHonda reported FY2025 revenue of JPY 21.7 trillion, a 6.2% year-over-year increase, driven by strong North American demand and favorable currency tailwinds. The company faces intensifying competition from Chinese EV manufacturers in Asia and is exploring a potential merger with Nissan as part of broader Japanese automotive consolidation. Honda's engineering culture, global manufacturing scale, and brand credibility in reliability position it as a resilient and well-capitalized incumbent navigating the EV transition.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.